Patent application number | Description | Published |
20090261385 | BIPOLAR TRANSISTOR WITH ENHANCED BASE TRANSPORT - A bipolar transistor includes a base layer design and a method for fabricating such a bipolar transistor that employ a built-in accelerating field focused on a base region adjacent to a collector, where minority carrier transport is otherwise retarded. The accelerating field of the base layer includes on average, a relatively low p-doping level in a first region proximate to the collector and a relatively high p-doping level in a second region proximate to an emitter. Alternatively, the accelerating field can be derived from band gap grading, wherein the grade of band gap in the first region is greater than the grade of band gap in the second region, and the average band gap of the first region is lower than that of the second region. | 10-22-2009 |
20120175681 | Method and Layer Structure for Preventing Intermixing of Semiconductor Layers - A semiconductor device includes an etch-stop layer between a first layer of a field-effect transistor and a second layer of a bipolar transistor, each of which includes at least one arsenic-based semiconductor layer. A p-type layer is between the second layer and the etch-stop layer, and the device can include an n-type layer deposited between the etch-stop layer and p-type layer. The p-type layer provides an electric field that inhibits intermixing of the InGaP layer with layers in the first and second layers. | 07-12-2012 |
20120326211 | BIPOLAR HIGH ELECTRON MOBILITY TRANSISTOR AND METHODS OF FORMING SAME - An epilayer structure includes a field-effect transistor structure and a heterojunction bipolar transistor structure. The heterojunction bipolar transistor structure contains an n-doped subcollector and a collector formed in combination with the field-effect transistor structure, wherein at least a portion of the subcollector or collector contains Sn, Te, or Se. In one embodiment, a base is formed over the collector; and an emitter is formed over the base. The bipolar transistor and the field-effect transistor each independently contain a III-V semiconductor material. | 12-27-2012 |
20140175519 | METHOD AND LAYER STRUCTURE FOR PREVENTING INTERMIXING OF SEMICONDUCTOR LAYERS - A semiconductor device includes an etch-stop layer between a first layer of a field-effect transistor and a second layer of a bipolar transistor, each of which includes at least one arsenic-based semiconductor layer. A p-type layer is between the second layer and the etch-stop layer, and the device can include an n-type layer deposited between the etch-stop layer and p-type layer. The p-type layer provides an electric field that inhibits intermixing of the InGaP layer with layers in the first and second layers. | 06-26-2014 |
Patent application number | Description | Published |
20080271070 | Negotiated access to promotional insertion opportunity - A technique (and corresponding system) for controlling access to insertion opportunities in a multi-channel streaming media system is provided. The technique receives parameters for access to the insertion opportunities from multiple advertisers, such as desired audience viewership profile characteristics. The technique evaluates the received parameters to select which advertisers gain access to the insertion opportunities to place promotional content. The technique analyzes an audience of the placed promotional content and identifies which of the possible promotional content optimizes the value of the insertion opportunities or other maxima. Unlike traditional advertising in which advertisers pay per expected viewership, the technique may be arranged to charge advertisers only for a targeted audience that viewed the placed promotional content. The technique thus enables advertisers to access disparate insertion opportunities and to target an audience at lower cost without having to establish relationships with owners of insertion opportunities. | 10-30-2008 |
20110295700 | Auctioning Segmented Avails - Various embodiments enable auctioning of segmented advertisement insertion opportunities, e.g., segmented avails, associated with distributed content. In at least some embodiments, bids from advertisers to place advertisements in conjunction with a segmented avail are obtained. The bids that are obtained can have different durations (e.g., 60, 30, 15 seconds) that can be selectively enabled by a segmented avail in various combinations to fill a total duration of the segmented avail. Ranking criteria and/or logic can be applied to rank the bids one to another. In at least some embodiments, the bids are ranked within groups corresponding to different time durations. Bids can be allocated to the segmented avail by testing one or more combinations of the bids and selecting a winning combination based at least in part upon a sum of the ranks associated with bids in the combination. | 12-01-2011 |
20120041827 | Demand Driven Avails - Various embodiments enable demand driven allocation of advertisement insertion opportunities, e.g., avails, that are associated with television content or other media entertainment from a provider. In at least some embodiments, projections for an inventory of avails from a provider are obtained using an iterative projection model. Auctions are conducted using the projected inventory to allocate the avails to advertisers using bids from the advertisers. Offers to purchase avails from the providers can be formed based on these auctions and submitted to the provider on behalf of the advertisers. Based on a response from the provider to these offers, yield analysis can be performed to update the projection model to reflect results of the submitted offers. Projections for subsequent iterations can then make use of the updated projection model. | 02-16-2012 |
20130282495 | Auctioning Segmented Avails - Various embodiments enable auctioning of segmented advertisement insertion opportunities, e.g., segmented avails, associated with distributed content. In at least some embodiments, bids from advertisers to place advertisements in conjunction with a segmented avail are obtained. The bids that are obtained can have different durations (e.g., 60, 30, 15 seconds) that can be selectively enabled by a segmented avail in various combinations to fill a total duration of the segmented avail. Ranking criteria and/or logic can be applied to rank the bids one to another. In at least some embodiments, the bids are ranked within groups corresponding to different time durations. Bids can be allocated to the segmented avail by testing one or more combinations of the bids and selecting a winning combination based at least in part upon a sum of the ranks associated with bids in the combination. | 10-24-2013 |
Patent application number | Description | Published |
20090011861 | GOLF BALLS CONTAINING INTERPENETRATING POLYMER NETWORKS - The present invention is directed to a golf ball that contains an interpenetrating polymer network, or IPN, including at least two polymeric components. These IPNs may be present in any golf ball layer, although in an intermediate or cover layer in one preferred embodiment. The present invention is also directed to methods of forming a golf ball containing an IPN in one or more of the layers. | 01-08-2009 |
20100062877 | CASTABLE GOLF BALL COMPONENTS USING ACRYLATE FUNCTIONAL RESINS - Golf ball components, such as cores, intermediate layers, and covers, formed with compositions including precursors with acrylate functionality crosslinked with a curing agent. | 03-11-2010 |
20110165967 | CASTABLE GOLF BALL COMPONENTS USING ACRYLATE FUNCTIONAL RESINS - Golf ball components, such as cores, intermediate layers, and covers, formed with compositions including precursors with acrylate functionality crosslinked with a curing agent. | 07-07-2011 |
20110207557 | POLYUREA COATINGS FOR GOLF EQUIPMENT - A polyurea-based curable coating for use with sports equipment, such as golf balls, golf shoes, golf clubs, footballs, billiard balls, baseballs, and the like, of which the coating may be cured over time, with heat, or a combination thereof, providing enhanced adhesion to equipment surfaces, improved abrasion resistance, and increased water resistance. | 08-25-2011 |
Patent application number | Description | Published |
20090076263 | ELIMINATION OF HETEROGENEOUS OR MIXED CELL POPULATION IN TUMORS - Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor. | 03-19-2009 |
20090081705 | NOVEL PEPTIDES AND COMPOSITIONS WHICH MODULATE APOPTOSIS - The present invention is directed to novel peptides and compositions capable of modulating apoptosis in cells, and to methods of modulating apoptosis employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to a novel peptide designated the “GD domain,” which is essential both to Bak's interaction with Bcl-x | 03-26-2009 |
20090291090 | ANTI-CD33 ANTIBODIES AND METHOD FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 11-26-2009 |
20100028346 | NOVEL SYNERGISTIC EFFECTS - The present invention encompasses a combination of at least one conjugate and one or more chemotherapeutic agent(s) which when administered exerts an unexpectedly enhanced therapeutic effect. The therapeutic effectiveness of the combination is greater than that of the conjugate alone or the administration of one or more of the drug(s) without the conjugate. The present invention is also directed to compositions comprising at least one conjugate and at one or more of chemotherapeutic agent and to methods of treating cancer using at least one conjugate and at least one or more of chemotherapeutic agent (s). The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of one or more chemotherapeutic agent(s) and at least one conjugate. In each case, such combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the anticancer agent(s) alone. | 02-04-2010 |
20110008840 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 01-13-2011 |
20110206700 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 08-25-2011 |
20110319612 | ELIMINATION OF HETEROGENEOUS OR MIXED CELL POPULATION IN TUMORS - Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor. | 12-29-2011 |
20120282282 | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates - The invention relates to charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of using the same to reduce ocular toxicity associated with administration of antibody drug conjugates. | 11-08-2012 |
20130078241 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 03-28-2013 |
20140093523 | Anti-Integrin Immunoconjugates, Methods and Uses - The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog. | 04-03-2014 |
20140248267 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 09-04-2014 |
Patent application number | Description | Published |
20110177064 | Compositions and Methods for Treatment of Ovarian Cancer - The present invention relates to surprisingly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g.,, an immunoconjugate) in combination with at least two chemotherapeutic agents (in particular a taxane compound and a platinum compound), improves the therapeutic index in the treatment of ovarian cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus additional chemotherapeutic agents have a synergistic effect in the ovarian cancer therapeutic index. The present invention also provides methods of modulating the growth of selected cell populations, such as ovarian cancer cells, by administering a therapeutically effective amount of such combinations. | 07-21-2011 |
20120269827 | Compositions and Methods for Treatment of Ovarian, Peritoneal, and Fallopian Tube Cancer - The present invention relates to highly effective anti-cancer drug combinations, pharmaceutical compositions comprising the same, and uses thereof in the treatment of ovarian, peritoneal, or fallopian tube cancer. In particular, the present invention is based on the discovery that the administration of a CD56 antibody linked to a cytotoxic compound (e.g., an immunoconjugate) in combination with a chemotherapeutic agent (in particular a gemcitabine compound, a topotecan compound, and a doxorubicin compound), improves the therapeutic index in the treatment of ovarian, peritoneal, or fallopian tube cancer over and above the additive effects of the anticancer agents used alone. In one embodiment of the invention, combinations of the CD56 antibody, or fragment thereof, linked to a cytotoxic compound plus an additional chemotherapeutic agent have a synergistic effect in the ovarian cancer therapeutic index. | 10-25-2012 |